Livzon
Global Phase 3 Randomized Trial to evaluate efficacy, safety, immunogenicity of Recombinant SARS COV-2 fusion protein vaccine against COVID 19 in healthy adults after vaccination of 2 doses of inactivated vaccines
Completed
Completed
Global Phase 3 Randomized Trial to evaluate efficacy, safety, immunogenicity of Recombinant SARS COV-2 fusion protein vaccine against COVID 19 in healthy adults after vaccination of 2 doses of inactivated vaccines